Statizoid

Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) vs Portugal: Antiretroviral therapy coverage for PMTCT

Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
20.1%
in 2024
Portugal
96.0%
in 2009
Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) rank
14th
Portugal rank
15th

Antiretroviral therapy coverage for PMTCT over time

  • Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
  • Portugal
020406080100200020122024

How they compare

Portugal currently reports 96.0% against 20.1% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), a difference of 75.9%.

That makes Portugal's figure about 4.8 times Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)'s.

Across all 10 years both countries report, Portugal has been ahead every year.

Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 14th and Portugal ranks 15th of 15 groups.

Portugal has averaged higher in every one of the 1 decades both report.

Frequently asked questions

Which has higher antiretroviral therapy coverage for pmtct, Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) or Portugal?
Portugal, at 96.0% against 20.1% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) as of 2009.
What is the difference in antiretroviral therapy coverage for pmtct between Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) and Portugal?
75.9%, with Portugal ahead.
How many years of comparable data are there for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) and Portugal?
10 years are reported by both, from 2000 to 2009.
How do Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) and Portugal rank globally for antiretroviral therapy coverage for pmtct?
Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 14th and Portugal ranks 15th of 15 groups.
Where does this data come from?
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) vs Portugal: Antiretroviral therapy coverage for PMTCT. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 19 September 2026, from https://health.statizoid.com/compare/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/middle-east-north-africa-afghanistan-and-pakistan-ida-and-ibrd/portugal/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/compare/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/middle-east-north-africa-afghanistan-and-pakistan-ida-and-ibrd/portugal/">Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) vs Portugal: Antiretroviral therapy coverage for PMTCT</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).